Handok strengthens global pharma partnerships
By Kim, Jin-Gu | translator Kang, Shin-Kook
24.05.28 05:38:28
가나다라
0
Signed a licensing deal with Biocon for liraglutide obesity drug…will be commercialized after 2025
Introduced rare disease drugs, Empaveli and Doptelet, at the end of last year…minimized the gap left by Soliris
In February, Handok launched ‘Aprovasc,‘ a combination therapy for hypertension that was co-developed with Sanofi
At the end of last year, Handok signed deals with the Dutch company Argenx and Swedish biopharmaceutical company Sobi for three rare disease treatments. This year, the company also launched a combination therapy for high blood pressure co-developed with Sanofi.
On May 24, Handok signed a deal with India’s global pharmaceutical company Biocon for liraglutide, a GLP-1 agonist used to treat diabetes and obesity.
Handok plans to fill the pipeline gap caused by patent expiration and license endings through these partnerships.
Handok signs a licensing deal with India’s pharmaceu
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)